Gilead, Hookipa pen hepatitis B, HIV research collaboration

Gilead, Hookipa pen hepatitis B, HIV research collaboration

Source: 
Fierce Biotech
snippet: 

Gilead has licensed immunization technologies from Hookipa Biotech for use against hepatitis B and HIV. The big biotech is paying $10 million (€8.5 million) upfront and committing to milestones that could exceed $400 million to snag exclusive rights to two technologies in the indications.